Effect of montelukast on single-dose theophylline pharmacokinetics

American Journal of Therapeutics

Volumn 5, Issue 3, 1998, Pages 189-195

  Malmstrom, Kerstin ^a   Schwartz, Jules ^a   Reiss, Theodore F ^a   Sullivan, Timothy J ^b   Reese, James H ^b   Jauregui, Luis ^b   Miller, Kristen ^b   Scott, Molly ^b   Shingo, Sumiko ^a   Peszek, Iza ^a   Larson, Patrick ^a   Ebel, David ^a   Hunt, Thomas L ^c   Huhn, Richard D ^d,e   Bachmann, Kenneth ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c Pharmaco International Inc   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Asthma; Clinical dosage; Montelukast; Pharmacokinetics; Theophylline

Indexed keywords

ANTIASTHMATIC AGENT; MONTELUKAST; THEOPHYLLINE; THEOPHYLLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 7144264424     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199805000-00010     Document Type: Review

References (15)

1. Weinberger M, Hendeles L: Theophylline in asthma. N Engl J Med 1996;334:1380-1388.
2. Barr J, Schumacher G, Luks D, et al: Mild theophylline-related adverse reactions and serum theophylline concentration. Am J Hosp Pharm 1994;15:2688-2692.
3. Troeger U, Meyer FP: Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Clin Pharmacokinet 1995;28:287-293.
4. Robson RA, Miners JO, Matthews AP, et al: Characterization of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem Pharmacol 1988;37:1651-1659.
5. Jones TR, Labelle M, Belley M, et al: Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995;73:191-201.
6. 1 receptor antagonist, improves the signs and symptoms of asthma over a 3-month treatment period. Eur Res J 1996;9:273s.
7. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-534.
8. Jonkman J, Upton R: Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984;9:309-334.
9. Sarkar MA, Hunt C, Guzelian PS, et al: Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992;20:31-37.
10. Gu L, Gonzalez FJ, Kalow W, et al: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992;2:73-77.
11. Tjia JF, Colbert J, Back DJ: Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996;276:912-917.
12. 4 receptor antagonist, in humans. Drug Metab Dispos 1997; 25:1022-1031.
13. Hill HD, Jolley ME, Wang CHJ, et al: Fluorescence polarization immunoassay for theophylline, clinical correlation and reagent stability. Clin Chem [Abstract 310] 1981;27:1086.
14. Amin RD, Cheng H, Rogers JD: Determination of MK-0476 in human plasma by liquid chromatography. J Pharm Biomed Anal 1995;13:155-158.
15. 4-receptor antagonist in healthy volunteers. Br J Clin Pharmacol 1991;40:277-280.